Sign Out
Pharmacotherapeutic group: Antiprotozoal. ATC code: P01AB07.
Pharmacology: Pharmacodynamics: Secnidazole is a semisynthetic derivative of the series of nitro-imidazoles. It has antiprotozoal and antiparasitic properties and acts as an amoebicide essentially in tissue. Acts as parasiticide against Entamoeba histolytica and has activity on Giardia lamblia and Trichomonas vaginalis.
Pharmacokinetics: Absorption: Secnidazole is absorbed quickly after oral administration and peak concentrations were achieved within 1.5-3 hours. Absolute bioavailability is near 100% when a single dose of 0.5-2g secnidazole is taken orally. In the range of the application dose, the dose is in direct ratio with peak plasma concentration (Cmax) and plasma drug concentration area under the curve (AUC).
Distribution: Secnidazole is not widely distributed in vivo. Steady state volume (49.2 L) is very small and only 15% total plasma blood dosage is combined with plasma protein or globulin. Serum drug concentration is similar to that in gingival crevice secretion, thus this product can easily infiltrates into gingiva. Besides, it can also permeate placental membrane and found in breast milk.
Metabolism: Secnidazole is mainly metabolized in the liver.
Elimination: The plasma half-life of elimination of secnidazole is 25 hours. The removal is essentially urinary, is slow (16% of the ingested dose is excreted in 72 hours and 50% of the ingested dose is excreted in 120 hours).
Secnidazole crosses the placenta and passes into breast milk.
Continue with Google